In Vitro Organ Imaging Device (IV-OID) with integrated Biosensing and Real-Time Imaging Capability: Proof-of-Principle using a Human Placental Model

具有集成生物传感和实时成像功能的体外器官成像设备 (IV-OID)：使用人类胎盘模型进行原理验证

• 批准号: BB/T012056/1
• 负责人: Aras Kadioglu
• 金额: $ 19.19万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FT012056%2F1
• 关键词: Vitro; Organ; Imaging; Device; IV

Bringing a new drug or a vaccine to the market is a complex task for both researchers and drug manufacturers. Recent studies reported that the costs of developing a drug had nearly doubled every decade between 1950 and 2010. Today's drug or vaccine candidates are more likely to fail in clinical trials compared to 40 years ago. Different reasons have been put forth explaining the high failure rate, one of them being that preclinical models cannot fully recapitulate the human physiology. Hence, the need for more complex and predictive in vitro models which can better mimic the human response to drug or vaccine is essential. Here, we propose to develop a novel technological platform i..e, an In Vitro Organ Imaging Device (IV-OID) based on the use of hollow fibre technology and imaging-compatible materials. The platform aims to address the following objectives:(a) Creation of a human tissue surrogate platform that researchers can use e.g., to test drugs, in lieu of animals or humans.(c) Engineering of an organ-like model systems as a means of providing insight into the mechanisms underlying infectious diseases.(b) High-resolution visualisation of how pathogens behave and lead to diseases using state-of-the art microscopes.Our technological platform will be validated through the set up of a human placental model and the evaluation of its barrier functions in relation to microbial pathogens such as Toxoplasma Gondii. If successful, the IV-OID will be made available to the wider academic and industrial communities through our industrial project partner, Flocel Inc.

对于研究人员和药品制造商来说，将一种新药或疫苗推向市场是一项复杂的任务。最近的研究报告称，从1950年到2010年，研发一种药物的成本每十年几乎翻一番。与40年前相比，今天的候选药物或疫苗更有可能在临床试验中失败。人们提出了不同的原因来解释失败率高的原因，其中之一是临床前模型不能完全概括人类生理。因此，需要更复杂和更具预测性的体外模型，以更好地模拟人类对药物或疫苗的反应。在这里，我们建议开发一种新的技术平台，即基于中空纤维技术和成像兼容材料的体外器官成像设备(IV-OID)。该平台旨在解决以下目标：(A)创建一个人体组织代理平台，研究人员可以使用它来测试药物，例如代替动物或人类。(C)设计一个类似器官的模型系统，作为深入了解传染病潜在机制的手段。(B)使用最先进的显微镜高分辨率显示病原体的行为和导致疾病的方式。我们的技术平台将通过建立人体胎盘模型和评估其与弓形虫等微生物病原体的屏障功能来验证。如果成功，IV-OID将通过我们的工业项目合作伙伴FLocel Inc.提供给更广泛的学术界和工业界。